BEIJING -- (Marketwire) -- 06/10/11 -- Today, www.GlobalEquityReporter.com announced its research report highlighting Kraig Biocraft Laboratories, Inc. (PINKSHEETS: KBLB) and Titan Pharmaceuticals, Inc. (OTCBB: TTNP). Full report download is available at www.GlobalEquityReporter.com/access.php.
It is predicted that the recent health care reform legislation will negatively affect industry profitability over the next few years; however, eventual benefits will accrue from significant expansion of the market, with new coverage potentially being provided to 32 million currently uninsured Americans. Firms with well-defined growth prospects and generous dividend yield, should sustain as they should perform relatively well over the coming quarters. Pharmaceuticals remain one of the widest-margin U.S. industries, with prospects enhanced by demographic growth in the elderly (which account for about 33% of industry sales) and new drugs stemming from discoveries in genomics and biotechnology.
Global Equity is reporting on Kraig Biocraft Laboratories, Inc. as it is a biotechnology company focused on the development of high performance polymers. Kraig works in cooperation with leading universities in the fields of genetics and genetic engineering to develop new recombinant fibers and materials which the company believes will have broad commercial applications. The full report and profile on Kraig Biocraft Laboratories, Inc. (PINKSHEETS: KBLB) is available here: www.GlobalEquityReporter.com/get.PDF.1824.php.
Global Equity Reporter brings Titan Pharmaceuticals, Inc. because it too is a biopharmaceutical company developing proprietary therapeutics primarily for the treatment of central nervous system (CNS) disorders. The Company is focused primarily on clinical development of the following products: Probuphine for the treatment of opioid addiction; Iloperidone: for the treatment of schizophrenia and related psychotic disorders; and Spheramine for the treatment of advanced Parkinson's disease. The Company is also utilizing grants from government agencies to fund development of its product candidates. The full report and profile on Titan Pharmaceuticals, Inc. (OTCBB: TTNP) is available here: www.GlobalEquityReporter.com/get.PDF.1937.php.
About Global Equity Reporter
Global Equity Reporter is a premier source for microcap research -- providing a wide range of due diligence and investment insight on stocks all over the market Global Equity Reporter's primary focus is to alert our valued subscribers to small cap and microcap companies poised for explosive movement in the market. As every investor knows, timing in the market is critical, and that's where Global Equity Reporter delivers.
Contact:
Alexander Griffin
Email Contact
www.GlobalEquityReporter.com
